[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neural-tube-defects\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neural-tube-defects":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,83,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100572541","folic-acid-salt-study-fisfa-zambia-100572541",false,"NCT06734611","Folic Acid Salt Study (FISFA Zambia)","Effectiveness Study of Folic Acid Fortified Iodized Salt to Increase Folate Concentrations in Women of Reproductive Age in Zambia, a Non-fortifying Country","Inclusion Criteria:\n\n* Voluntary participation in the study\n* Do not intend to get pregnant\n* Not lactating or pregnant\n* Live alone or with a partner if they can be compliant and not share the study salt.\n* Aged between 18 and 45 years\n\nExclusion Criteria:\n\n* Pregnant or lactating",true,"FEMALE","18 Years","45 Years",{"count":21,"type":22},250,"ESTIMATED","INTERVENTIONAL",[25],"NA","Question: How effective is fortified iodized salt with folic acid (FISFA) in increasing serum and red blood cell folate in non-lactating, non-pregnant women of reproductive age in the country of Zambia who do not have active food fortification with a folic acid program?\n\nParticipants will:\n\n* Consume salt with folic acid instead of their regular salt for 6 months\n* Have a blood draw 4 times\n* Fill out surveys",[28,29],"Folate Deficiency","Neural Tube Defects",[31,32,33,34,35,36,37,38,39,40,41,42],"folic acid","iodine","salt","serum folate","red blood cell folate","prevention","folate insufficiency","Malnutrition","Nervous System Malformations","Spinal Dysraphism","Vitamin B9","Micronutrients","RECRUITING","2026-06-24",{"date":46,"type":47},"2026-06-29","ACTUAL",{"date":49,"type":47},"2026-04-10",{"date":51,"type":22},"2028-12-31",{"name":53,"class":54},"University of Alabama at Birmingham","OTHER",2,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100490955","safety-and-efficacy-of-devices-used-in-fetoscopic-neural-tube-defect-repair-cases-100490955","NCT05672849","Safety and Efficacy of Devices Used in Fetoscopic Neural Tube Defect Repair Cases","Inclusion Criteria:\n\n* Patients who elect to undergo fetoscopic neural tube defect repair\n\nExclusion Criteria:\n\n* Patients who do not elect to undergo fetoscopic neural tube defect repair",{"count":63,"type":22},100,[25],"The purpose of the study is to evaluate the safety and efficacy of devices used in patients undergoing fetoscopic neural tube defect repair.",[29],[68,69,70,71,72],"myelomeningocele","MMC","NTD","neural tube defect","spina bifida","2025-12-08",{"date":75,"type":47},"2025-12-15",{"date":77,"type":47},"2022-11-14",{"date":79,"type":22},"2027-12",{"name":81,"class":54},"Michael A Belfort",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":70,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":82},"100588834","fetoscopic-neural-tube-defect-repair-100588834","NCT06946563","Fetoscopic Neural Tube Defect Repair","Fetoscopic Neural Tube Defect Repair: Observational Pilot Study","Inclusion Criteria:\n\n* Maternal age 18 years or older\n* Capable of consenting for their own participation in the study\n* Decision to have fetoscopic repair following counseling of all options\n* Open spina bifida with the upper boundary between T1 and S1\n* Gestational age between 24 0\u002F7 to 26 6\u002F7 weeks' gestation at the time of surgery\n* Normal karyotype and\u002For normal chromosomal microarray by invasive testing. In the case of a microdeletion, microduplication, or variant of uncertain significant, the decision to include or exclude will be at the discretion of the Principal Investigators.\n* Absence of major cardiac anomalies confirmed by fetal echocardiogram\n* Adequate social support throughout pregnancy\n* Parental or guardian willingness to undergo follow-up evaluations of the child after birth\n\nExclusion Criteria:\n\n* Multiple gestation\n* Major fetal anomalies unrelated to the neural tube defect\n* Kyphosis in fetus of 30 degrees or more as assessed by ultrasound or MRI\n* Previous spontaneous singleton preterm birth prior to 37 weeks\n* Presence of cervical cerclage at the time of surgery or history of cervical insufficiency\n* Cervical length less than 20 mm by endovaginal ultrasound\n* Placenta previa or evidence of placental abruption\n* Technical factors such as large uterine fibroids, uterine anomalies, or fetal membrane separation for which the risks of surgery are deemed to outweigh the benefits\n* Maternal obesity precluding surgical access with a BMI \\> 45 or if the Principal Investigator determines the body habitus to be technically challenging\n* Alloimmunization in pregnancy including Kell sensitization or a history of neonatal alloimmune thrombocytopenia\n* Maternal HIV or Hepatitis B positive status. If the patient's HIV or Hepatitis B status is unknown, the patient must be tested and found to be negative prior to surgery\n* Known Hepatitis C positivity. If the patient's Hepatitis C status is known, they do not need to be screened\n* Maternal medical condition which is a contraindication to surgery or general anesthesia. This includes previous hysterotomy in the active segment of the uterus\n* Maternal medical co-morbidities which would significantly increase the risk of spontaneous or iatrogenic preterm delivery\n* Inability of the patient to comply with travel and follow-up requirements of the study\n* Patient not meeting psychosocial criteria determined by fetal care social worked to comply with the medical care and plan for follow ups\n* Participation in another interventional study that influences maternal and fetal morbidity and mortality\n* Known history of hypersensitivity to collagen products or chondroitin materials",{"count":91,"type":22},25,"OBSERVATIONAL","This is a single-arm prospective study to record maternal and neonatal outcomes on subjects who undergo fetoscopic repair of Neural Tube Defects (NTD) at Oregon Health \\& Science University (OHSU). Fetoscopic repair will take place between 24 weeks 0 days and 27 weeks 6 days gestation. Surgical, post-operative, delivery, and neonatal outcomes will be collected.",[29,95],"Spina Bifida",[97,98],"Fetal Surgery","Fetoscopy","2025-04-20",{"date":101,"type":47},"2025-04-27",{"date":103,"type":47},"2023-04-01",{"date":105,"type":22},"2033-04",{"name":107,"class":54},"Oregon Health and Science University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":55},"100351453","laparotomy-versus-percutaneous-endoscopic-correction-of-myelomeningocele-100351453","NCT03856034","Laparotomy Versus Percutaneous Endoscopic Correction of Myelomeningocele","In Utero Endoscopic Correction of Myelomeningocele: Laparotomy Versus Percutaneous - A Pilot Study","Inclusion Criteria:\n\n1. Myelomeningocele (including myeloschisis) at level T1 through S1 with hindbrain herniation. Lesion level and hindbrain herniation will be confirmed by MRI and ultrasonography.\n2. Maternal age ≥18 years.\n3. Gestational age of 19 to 27 6\u002F7 weeks' gestation as determined by clinical information and evaluation of first ultrasound.\n4. Balanced karyotype with written confirmation of culture results. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is at 24 weeks or more.\n5. Positive evaluation of social work consult indicating the patient is capable of consenting to the procedure and has the appropriate social support system to participate in the study.\n6. Positive evaluation from pediatric neurology consult.\n7. Willing to remain in the greater Wellington or Pasadena area (within a 30-minute car ride) for remainder of the pregnancy and deliver at Wellington Regional Medical Center or Huntington Memorial Hospital for postnatal management. The participants must be willing to return to our center for the 12, 24, 30, 48, and 60 months for follow-up evaluation.\n\nExclusion Criteria:\n\n1. Multiple gestation\n2. Insulin-dependent pregestational diabetes\n3. Presence of a fetal anomaly not related to myelomeningocele. A fetal echocardiogram will be conducted before surgery and if the finding is abnormal, the patient will be excluded.\n4. Fetal kyphosis of 30 degrees or more, assessed by ultrasound or MRI.\n5. Presence of uterine cervical cerclage or history of incompetent cervix.\n6. Placenta previa or placental abruption.\n7. Short cervix \\\u003C 25 mm measured by cervical ultrasound.\n8. Obesity as defined by body mass index (BMI) of 35 or greater.\n9. History of previous spontaneous singleton delivery prior to 37 weeks.\n10. Maternal-fetal Rh isoimmunization, Kell sensitization or a history of neonatal alloimmune thrombocytopenia.\n11. Maternal HIV or Hepatitis-B status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis B status is unknown, the patient must be tested and found to have negative results before she can be enrolled.\n12. Known Hepatitis-C positivity. If the patient's Hepatitis C status is unknown, she does not need to be screened.\n13. Uterine anomaly such as large (greater than 6 cm) fibroids, cervical fibroids or multiple fibroids or Mullerian duct abnormality.\n14. Other maternal medical condition which is a contraindication to surgery or anesthesia.\n15. Patient does not have a support person (e.g., husband, partner, parents).\n16. Inability to comply with the travel and follow-up requirements of the study.\n17. Patient does not meet psychosocial criteria as determined by the social worker evaluation.\n18. Participation in another intervention study that influences maternal and fetal morbidity and mortality.\n19. Maternal hypertension as determined by the investigator, which would increase the risk of preeclampsia or preterm delivery (including, but not limited to: uncontrolled hypertension, chronic hypertension with end organ damage and new onset hypertension in current pregnancy).\n20. Bicornuate uterus or any other uterine malformation the PI decides is not safe for surgery.\n21. Nickel allergy.\n22. Maternal request to undergo open fetal surgery for the antenatal correction of open spina bifida at our institution primarily or after failed fetoscopic approach.\n23. Known maternal hypersensitivity to bovine collagen or chondroitin materials.",{"count":116,"type":22},12,[25],"The purpose of this study is to evaluate the feasibility of a fetoscopic surgical technique for antenatal correction of fetal myelomeningocele. Two surgical approaches will be utilized. The percutaneous approach will be offered to participants with a posterior placenta. The laparotomy\u002Futerine exteriorization approach will be offered to participants regardless of placental location.",[29,95,120,121],"Myelomeningocele","Chiari Malformation",[72,68,71,123,124,125,126],"chiari malformation","fetoscopy","percutaneous","fetus","2019-11-11",{"date":129,"type":47},"2019-11-13",{"date":131,"type":47},"2018-11-02",{"date":133,"type":22},"2027-12-31",{"name":135,"class":54},"USFetus"]